STOCK TITAN

Karuna Therapeutics Inc - KRTX STOCK NEWS

Welcome to our dedicated news page for Karuna Therapeutics (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karuna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karuna Therapeutics's position in the market.

Rhea-AI Summary
Karuna Therapeutics, Inc. announces the NDA review for KarXT for schizophrenia treatment, Phase 3 trial results, key pipeline highlights, leadership appointments, financial results, and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
earnings
-
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.71%
Tags
acquisition
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.93%
Tags
acquisition
-
Rhea-AI Summary
Bristol Myers Squibb (BMY) will acquire Karuna Therapeutics, Inc. (KRTX) for $14.0 billion, aiming to enhance their growth and diversify the portfolio in the neuroscience space. The transaction is expected to close in the first half of 2024, with KarXT, a first-in-class treatment for schizophrenia and Alzheimer's disease psychosis, as the key asset.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
Rhea-AI Summary
Bristol Myers Squibb (BMY) will acquire Karuna Therapeutics, Inc. (KRTX) for $14.0 billion, aiming to enhance their growth and diversify the portfolio in the neuroscience space. The transaction is expected to close in the first half of 2024, with KarXT, a first-in-class treatment for schizophrenia and Alzheimer's disease psychosis, as the key asset.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.71%
Tags
acquisition
Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire Karuna Therapeutics, Inc. (KRTX) for $14 Billion, Expanding Its Portfolio in Neuroscience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire Karuna Therapeutics, Inc. (KRTX) for $14 Billion, Expanding Its Portfolio in Neuroscience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.71%
Tags
acquisition
-
Rhea-AI Summary
Karuna Therapeutics, a biopharmaceutical company (NASDAQ: KRTX), announced statistically significant and clinically meaningful improvements in positive and negative symptoms of schizophrenia with their drug KarXT. The dual M1/M4 muscarinic agonist showed a distinct tolerability profile and a potential to redefine the treatment landscape for schizophrenia. The Phase 3 EMERGENT-2 trial published in The Lancet demonstrated a 9.6-point reduction in PANSS total score compared to placebo, with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
acquisition clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
Karuna Therapeutics Inc

Nasdaq:KRTX

KRTX Rankings

KRTX Stock Data

12.05B
36.30M
4.91%
86.5%
4.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About KRTX

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip